

PEOPLE

Incyte Genomics (Palo Alto, CA) has named **Barry Ariko** to its board of directors. Mr. Ariko is currently chairman and CEO of Extricity Software, and previously served as senior vice president of the Netscape Enterprise Group at America Online as well as executive vice president and chief operating officer of Netscape.

Astex Technology (Cambridge, UK) has announced the appointments of **Robin Carr** as vice president of drug discovery and **Nigel Crockett** as commercial director. Both are newly created positions. Dr. Carr was most recently head of the chemical and analytical technology department at GlaxoWellcome UK, and Dr. Crockett joins Astex from Cantab Pharmaceuticals, where he served as director of business development.



Genta (Berkeley Heights, NJ) has announced the appointment of **Loretta M. Itri** to the positions of executive vice president, clinical research and development, and chief medical officer. Dr. Itri was most recently senior vice president, worldwide clinical affairs, and chief medical officer at Ortho Biotech.

EXACT Sciences (Maynard, MA) has named former US Senator **Connie Mack III** (R-Fla.) to its board of directors. He served two terms in the Senate, from 1988 to 2000, and was the chairman of the Senate Republican Conference and the third-ranking Republican member of the Senate. In addition, Senator Mack was a member of several committees, including the Joint Economic Committee (chairman), the Senate Finance Committee, and the Senate Cancer Coalition (co-chairman).

Charles B. Nemeroff has been appointed to the board of directors of Cypress Bioscience (San Diego, CA) and to a newly formed psychopharmacology advisory board focused on developing treatments for fibromyalgia syndrome. The company announced a strategic initiative into the treatment of FMS in January. Dr. Nemeroff is currently chairman of the Department of Psychiatry and Behavioral Sciences at the Emory University School of Medicine.

Robert Paré has been appointed to the board of directors of SignalGene (Montreal). A senior partner at the law firm of Faskin Martineau DuMoulin, Mr. Paré replaces Chantal Brunet, vice president, biotechnologies and health care sciences at Innovatech

Québec/Chaudière-Appalaches, who is leaving her seat on SignalGene's board.



Genset (Paris) has named **Denis Ravel** director of pharmaceutical development. Dr. Ravel was formerly head of the Metabolism Department of the French pharmaceutical company Servier.

Discovery Therapeutics (Richmond, VA) has announced the appointment of **Peter Savas** as president and CEO. Mr. Savas was most recently president and CEO of Unisyn Technologies.

Dan Shochat has been appointed vice president of pharmaceutical development at Deltagen (Menlo Park, CA). Dr. Shochat was formerly senior vice president and chief scientific officer of Coulter Pharmaceutical, where he also served as the vice president of research and development.

Cellular Genomics (Branford, CT) has appointed to its board of directors **Michael Steinmetz**, general partner of MPM Capital, and **Noubar Afeyan**, managing partner of AGTC Funds. Both venture capital firms recently participated in a \$22 million round of private equity financing for Cellular Genomics.

Kenneth E. Weg has been named to Millennium Pharmaceuticals' (Cambridge, MA) board of directors. Mr. Weg had a 38-year career with Bristol-Myers Squibb, culminating in the post of vice chairman. Upon his retirement in February, he founded and served as chairman of Clearview Projects, offering partnering and deal transaction services to biopharmaceutical companies and academic institutions.



Roger Wolff has joined emerGen (Salt Lake City, UT) as vice president of research, a newly created position. Dr. Wolff was formerly at Amgen, where he served most recently as an associate director of research and

head of the Departments of Molecular Genetics and Pharmacogenetics.

MacroChem (Lexington, MA) has named former Pharmacia & Upjohn president and CEO **John L. Zabriskie** as chairman of its board of directors. Before the 1995 merger of the two companies, Dr. Zabriskie served as president and CEO of Upjohn.